Sanofi Aventis Groupe

Jean-Pierre Lehner Appointed Chief Medical Officer

PARIS, February 11 /PRNewswire/ --     Sanofi-aventis announced today that 
Jean-Pierre Lehner, M.D., is
appointed Senior Vice-President, Chief Medical Officer (CMO). He was
previously Senior Vice President, Medical & Regulatory Affairs.

    Jean-Pierre Lehner reports to Marc Cluzel, Senior Vice President,
Research & Development, who declared : "The newly created role of Chief
Medical Officer is a further demonstration internally and externally of the
company's commitment to patient well being".

    Patient safety is of the utmost importance to sanofi-aventis. Given the
new tools available to enhance pharmacovigilance and monitor the safety of
products in development as well as those on the market, this position
combines all of the functions related to patient safety to enhance the
clarity of purpose and accountability within the company. Pharmacovigilance
and Regulatory Affairs will report to the CMO.

    The CMO will also chair the internal Benefit/Risk Assessment Committee
created in 2008 and which has direct accountability for its conclusions to
the CEO.

    Jean-Pierre Lehner holds a Medical degree from the School of Medicine
University of Paris, France. After spending four years as Chef de Clinique,
assistant of Paris Hospitals, Department of Cardiology (Pr Tricot), Hôpital
Bichat, Paris, France, Jean-Pierre Lehner joins Roussel Laboratories in 1981
as Medical Director (1981-1986), then he is named Medical Director of
Roussel-Uclaf (1986-1992). He is successively Senior Director of Clinical
Investigations of Sanofi Recherche (1992-1996), Scientific Senior Director of
Sanofi Winthrop (1996-2002), Vice President Medical Affairs Europe of
sanofiaventis (2003-2005). As from 2005, Jean-Pierre Lehner was Senior
Vice-President, Medical & Regulatory Affairs sanofi-aventis.

About sanofi-aventis

    Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York